The DOI matches its Crossref record; 57 of the 57 references it cites were found in a registry or an index.
Chemoenzymatic Glycoengineering of Intact IgG Antibodies for Gain of Functions
Open accessAbstract
The fine structures of Fc N-glycans can modulate the effector functions of IgG antibodies. It has been demonstrated that lack of the core fucose on the Fc N-glycans leads to drastic enhancement of antibody-dependent cellular cytotoxicity (ADCC), while terminal α2,6-sialylation of Fc glycan plays a critical role for the anti-inflammatory activity of human intravenous immunoglobulin (IVIG). We describe in this paper a highly efficient chemoenzymatic method for site-selective Fc glycoengineering of intact monoclonal antibody and IVIG. Two new glycosynthase mutants (EndoS-D233A and D233Q) were generated by site-directed mutagenesis of EndoS (an endoglycosidase from Streptococcus pyogenes ) and were found to be capable of efficiently transferring predefined N-glycans from corresponding glycan oxazolines to the Fc-deglycosylated intact IgGs without product hydrolysis. As a model study, rituximab (a therapeutic monoclonal antibody) was successfully transformed from mixtures of G0F, G1F, and G2F glycoforms to well-defined homogeneous glycoforms, including a fully sialylated (S2G2F) glycoform that may gain anti-inflammatory activity, a nonfucosylated G2 glycoform that showed significantly enhanced FcγIIIa receptor-binding activity, and an azido-tagged glycoform that can be further transformed into other glycoforms. We also found that EndoS could selectively remove the Fc N-glycans in the presence of FAB glycosylation. This finding, coupled with the remarkable transglycosylation activity of the EndoS glycosynthase mutants, permitted a highly selective glycoengineering of the IVIG's Fc glycans into a fully sialylated Fc glycoform, which may possess significantly enhanced anti-inflammatory activity. The glycoengineering approach described here provides a general platform to modulate the effector functions of IgG antibodies, enabling the optimization of therapeutic efficacy and gain of new functions of monoclonal antibodies and IVIG.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Fcγ receptors as regulators of immune responses
Nimmerjahn, F., & Ravetch, J. V. (2008) · Nature Reviews Immunology · doi:10.1038/nri2206 · Cited by 2,947
Cartron, G., Dacheux, L., Salles, G., Solal-Celigny, P., Bardos, P., Colombat, P., & Watier, H. (2002) · Blood · doi:10.1182/blood.v99.3.754 · Cited by 1,900
Shields, R. L., Lai, J., Keck, R., O'Connell, L. Y., Hong, K., Meng, Y. G., Weikert, S. H. A., & Presta, L. G. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m202069200 · Cited by 1,835
Anti-Inflammatory Activity of Immunoglobulin G Resulting from Fc Sialylation
Kaneko, Y., Nimmerjahn, F., & Ravetch, J. V. (2006) · Science · doi:10.1126/science.1129594 · Cited by 1,754
Shinkawa, T., Nakamura, K., Yamane, N., Shoji-Hosaka, E., Kanda, Y., Sakurada, M., Uchida, K., Anazawa, H., Satoh, M., Yamasaki, M., et al. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m210665200 · Cited by 1,413
Monoclonal antibody therapy of cancer
Adams, G. P., & Weiner, L. M. (2005) · Nature Biotechnology · doi:10.1038/nbt1137 · Cited by 1,246
From Mechanism to Mouse: A Tale of Two Bioorthogonal Reactions
Sletten, E. M., & Bertozzi, C. R. (2011) · Accounts of Chemical Research · doi:10.1021/ar200148z · Cited by 1,093
Fc receptor but not complement binding is important in antibody protection against HIV
Hessell, A. J., Hangartner, L., Hunter, M., Havenith, C. E. G., Beurskens, F. J., Bakker, J. M., Lanigan, C. M. S., Landucci, G., Forthal, D. N., Parren, P. W. H. I., et al. (2007) · Nature · doi:10.1038/nature06106 · Cited by 901
Recapitulation of IVIG anti-inflammatory activity with a recombinant IgG Fc
Anthony, R. M., Nimmerjahn, F., Ashline, D. J., Reinhold, V. N., Paulson, J. C., & Ravetch, J. V. (2008) · Science · doi:10.1126/science.1154315 · Cited by 849
Glycosylation as a strategy to improve antibody-based therapeutics
Jefferis, R. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2804 · Cited by 829
Koene, H. R., Kleijer, M., Algra, J., Roos, D., E.G.Kr. von dem Borne, A., & de Haas, M. (1997) · Blood · doi:10.1182/blood.v90.3.1109 · Cited by 794
Ferrara, C., Grau, S., Jäger, C., Sondermann, P., Brünker, P., Waldhauer, I., Hennig, M., Ruf, A., Rufer, A. C., Stihle, M., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1108455108 · Cited by 770
Umaña, P., Jean–Mairet, J., Moudry, R., Amstutz, H., & Bailey, J. E. (1999) · Nature Biotechnology · doi:10.1038/6179 · Cited by 764
The 3.2-Å crystal structure of the human IgG1 Fc fragment–FcγRIII complex
Sondermann, P., Huber, R., Oosthuizen, V., & Jacob, U. (2000) · Nature · doi:10.1038/35018508 · Cited by 719
Krapp, S., Mimura, Y., Jefferis, R., Huber, R., & Sondermann, P. (2003) · Journal of Molecular Biology · doi:10.1016/s0022-2836(02)01250-0 · Cited by 674
Best, M. D. (2009) · Biochemistry · doi:10.1021/bi9007726 · Cited by 644
Intravenous gammaglobulin suppresses inflammation through a novel TH2 pathway
Anthony, R. M., Kobayashi, T., Wermeling, F., & Ravetch, J. V. (2011) · Nature · doi:10.1038/nature10134 · Cited by 633
Yamane‐Ohnuki, N., Kinoshita, S., Inoue‐Urakubo, M., Kusunoki, M., Iida, S., Nakano, R., Wakitani, M., Niwa, R., Sakurada, M., Uchida, K., et al. (2004) · Biotechnology and Bioengineering · doi:10.1002/bit.20151 · Cited by 572
Identification of a receptor required for the anti-inflammatory activity of IVIG
Anthony, R. M., Wermeling, F., Karlsson, M. C. I., & Ravetch, J. V. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0810163105 · Cited by 547
Glycosylation of Recombinant Antibody Therapeutics
Jefferis, R. (2008) · Biotechnology Progress · doi:10.1021/bp040016j · Cited by 526
Anti-Inflammatory Actions of Intravenous Immunoglobulin
Nimmerjahn, F., & Ravetch, J. V. (2008) · Annual Review of Immunology · doi:10.1146/annurev.immunol.26.021607.090232 · Cited by 525
Guile, G. R., Rudd, P. M., Wing, D. R., Prime, S. B., & Dwek, R. A. (1996) · Analytical Biochemistry · doi:10.1006/abio.1996.0351 · Cited by 493
Acceptable changes in quality attributes of glycosylated biopharmaceuticals
Schiestl, M., Stangler, T., Torella, C., Čepeljnik, T., Toll, H., & Grau, R. (2011) · Nature Biotechnology · doi:10.1038/nbt.1839 · Cited by 473
Optimization of humanized IgGs in glycoengineered Pichia pastoris
Li, H., Sethuraman, N., Stadheim, T. A., Zha, D., Prinz, B., Ballew, N., Bobrowicz, P., Choi, B.-K., Cook, W. J., Cukan, M., et al. (2006) · Nature Biotechnology · doi:10.1038/nbt1178 · Cited by 428
Glycan optimization of a human monoclonal antibody in the aquatic plant Lemna minor
Cox, K. M., Sterling, J. D., Regan, J. T., Gasdaska, J. R., Frantz, K. K., Peele, C. G., Black, A., Passmore, D., Moldovan-Loomis, C., Srinivasan, M., et al. (2006) · Nature Biotechnology · doi:10.1038/nbt1260 · Cited by 421
Collin, M. (2001) · The EMBO Journal · doi:10.1093/emboj/20.12.3046 · Cited by 372
Niwa, R., Shoji-Hosaka, E., Sakurada, M., Shinkawa, T., Uchida, K., Nakamura, K., Matsushima, K., Ueda, R., Hanai, N., & Shitara, K. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-2068 · Cited by 325
Huhn, C., Selman, M. H. J., Ruhaak, L. R., Deelder, A. M., & Wuhrer, M. (2009) · PROTEOMICS · doi:10.1002/pmic.200800715 · Cited by 301
Structural Comparison of Fucosylated and Nonfucosylated Fc Fragments of Human Immunoglobulin G1
Matsumiya, S., Yamaguchi, Y., Saito, J.-I., Nagano, M., Sasakawa, H., Otaki, S., Satoh, M., Shitara, K., & Kato, K. (2007) · Journal of Molecular Biology · doi:10.1016/j.jmb.2007.02.034 · Cited by 278
The mechanisms of action of rituximab in the elimination of tumor cells
Johnson, P., & Glennie, M. (2003) · Seminars in Oncology · doi:10.1053/sonc.2003.50025 · Cited by 247
Yamaguchi, Y., Nishimura, M., Nagano, M., Yagi, H., Sasakawa, H., Uchida, K., Shitara, K., & Kato, K. (2006) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2005.10.002 · Cited by 204
Effect of SpeB and EndoS from Streptococcus pyogenes on Human Immunoglobulins
Collin, M., & Olsén, A. (2001) · Infection and Immunity · doi:10.1128/iai.69.11.7187-7189.2001 · Cited by 203
Wormald, M. R., Rudd, P. M., Harvey, D. J., Chang, S.-C., Scragg, I. G., & Dwek, R. A. (1997) · Biochemistry · doi:10.1021/bi9621472 · Cited by 191
NMR analysis demonstrates immunoglobulin G N-glycans are accessible and dynamic
Barb, A. W., & Prestegard, J. H. (2011) · Nature Chemical Biology · doi:10.1038/nchembio.511 · Cited by 186
Zhou, Q., Shankara, S., Roy, A., Qiu, H., Estes, S., McVie‐Wylie, A., Culm‐Merdek, K., Park, A., Pan, C., & Edmunds, T. (2008) · Biotechnology and Bioengineering · doi:10.1002/bit.21598 · Cited by 184
Aglycosylated immunoglobulin G1variants productively engage activating Fc receptors
Sazinsky, S. L., Ott, R. G., Silver, N. W., Tidor, B., Ravetch, J. V., & Wittrup, K. D. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0809257105 · Cited by 177
Strasser, R., Castilho, A., Stadlmann, J., Kunert, R., Quendler, H., Gattinger, P., Jez, J., Rademacher, T., Altmann, F., Mach, L., et al. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.014126 · Cited by 177
Three-Dimensional Elution Mapping of Pyridylaminated N-Linked Neutral and Sialyl Oligosaccharides
Takahashi, N., Nakagawa, H., Fujikawa, K., Kawamura, Y., & Tomiya, N. (1995) · Analytical Biochemistry · doi:10.1006/abio.1995.1201 · Cited by 175
Zou, G., Ochiai, H., Huang, W., Yang, Q., Li, C., & Wang, L.-X. (2011) · Journal of the American Chemical Society · doi:10.1021/ja208390n · Cited by 166
Self-citationEmerging Technologies for Making Glycan-Defined Glycoproteins
Wang, L., & Lomino, J. V. (2011) · ACS Chemical Biology · doi:10.1021/cb200429n · Cited by 138
Self-citationA Mechanistic Perspective of Monoclonal Antibodies in Cancer Therapy Beyond Target-Related Effects
Strome, S. E., Sausville, E. A., & Mann, D. L. (2007) · The Oncologist · doi:10.1634/theoncologist.12-9-1084 · Cited by 134
An endoglycosidase with alternative glycan specificity allows broadened glycoprotein remodelling.
Goodfellow, J., Baruah, K., Yamamoto, K., Bonomelli, C., Krishna, B., Harvey, D., Crispin, M., Scanlan, C. N., & Davis, B. (2012) · Journal of the American Chemical Society · doi:10.1021/ja301334b · Cited by 123
Guhr, T., Bloem, J., Derksen, N. I. L., Wuhrer, M., Koenderman, A. H. L., Aalberse, R. C., & Rispens, T. (2011) · PLoS ONE · doi:10.1371/journal.pone.0021246 · Cited by 113
Glycosylation in the Fc domain of IgG increases resistance to proteolytic cleavage by papain
Raju, T. S., & Scallon, B. J. (2006) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2006.01.030 · Cited by 112
Wei, Y., Li, C., Huang, W., Li, B., Strome, S. E., & Wang, L. (2008) · Biochemistry · doi:10.1021/bi800874y · Cited by 99
Self-citationOchiai, H., Huang, W., & Wang, L. (2008) · Journal of the American Chemical Society · doi:10.1021/ja805044x · Cited by 98
Self-citationUmekawa, M., Higashiyama, T., Koga, Y., et al. (2010) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2010.07.003 · Cited by 97
Branch-Specific Sialylation of IgG-Fc Glycans by ST6Gal-I
Barb, A. W., Brady, E. K., & Prestegard, J. H. (2009) · Biochemistry · doi:10.1021/bi901430h · Cited by 88
What's fueling the biotech engine—2010 to 2011
Aggarwal, S. (2011) · Nature Biotechnology · doi:10.1038/nbt.2060 · Cited by 79
Huang, W., Yang, Q., Umekawa, M., Yamamoto, K., & Wang, L. (2010) · ChemBioChem · doi:10.1002/cbic.201000242 · Cited by 71
Self-citationCrispin, M., Bowden, T. A., Coles, C. H., Harlos, K., Aricescu, A. R., Harvey, D. J., Stuart, D. I., & Jones, E. Y. (2009) · Journal of Molecular Biology · doi:10.1016/j.jmb.2009.02.033 · Cited by 66
Glycosylation of Antibody Therapeutics: Optimisation for Purpose
Roy, J. (2009) · Methods in molecular biology · doi:10.1007/978-1-59745-407-0_13 · Cited by 53
Molecular analysis of three gain-of-function CHO mutants that add the bisecting GlcNAc to N-glycans
Stanley, P. (2004) · Glycobiology · doi:10.1093/glycob/cwh136 · Cited by 51
Huang, W., Li, J., & Wang, L. (2011) · ChemBioChem · doi:10.1002/cbic.201000763 · Cited by 50
Self-citationThe Amazing Transglycosylation Activity of Endo-β-N-Acetylglucosaminidases
Wang, L. (2011) · Trends in Glycoscience and Glycotechnology · doi:10.4052/tigg.23.33 · Cited by 46
Self-citationAllhorn, M., Olsén, A., & Collin, M. (2008) · BMC Microbiology · doi:10.1186/1471-2180-8-3 · Cited by 42
Wan, H. Z., Kaneshiro, S., Frenz, J. H., & Cacia, J. (2001) · Journal of Chromatography A · doi:10.1016/s0021-9673(00)01168-7 · Cited by 29
Cited by
Carbohydrate-active enzymes (CAZymes) in the gut microbiome
Wardman, J. F., Bains, R. K., Rahfeld, P., & Withers, S. G. (2022) · Nature Reviews Microbiology · doi:10.1038/s41579-022-00712-1 · Cited by 597
Site-selective modification strategies in antibody–drug conjugates
Walsh, S. J., Bargh, J. D., Dannheim, F. M., Hanby, A. R., Seki, H., Counsell, A. J., Ou, X., Fowler, E., Ashman, N., Takada, Y., et al. (2021) · Chemical Society Reviews · doi:10.1039/d0cs00310g · Cited by 461
Sialylation of IgG Fc domain impairs complement-dependent cytotoxicity
Quast, I., Keller, C. W., Maurer, M. A., Giddens, J. P., Tackenberg, B., Wang, L.-X., Münz, C., Nimmerjahn, F., Dalakas, M. C., & Lünemann, J. D. (2015) · Journal of Clinical Investigation · doi:10.1172/jci82695 · Cited by 269
Self-citationGlycoconjugates: Synthesis, Functional Studies, and Therapeutic Developments
Shivatare, S. S., Shivatare, V. S., & Wong, C.-H. (2022) · Chemical Reviews · doi:10.1021/acs.chemrev.1c01032 · Cited by 257
In vitro glycoengineering of IgG1 and its effect on Fc receptor binding and ADCC activity
Thomann, M., Schlothauer, T., Dashivets, T., Malik, S., Avenal, C., Bulau, P., Rüger, P., & Reusch, D. (2015) · PLOS ONE · doi:10.1371/journal.pone.0134949 · Cited by 220
Metadata
- Authors
- Huang, W., Giddens, J., Fan, S.-Q., Toonstra, C., & Wang, L.-X.
- Venue
- Journal of the American Chemical Society
- Publisher
- American Chemical Society (ACS)
- Published
- 2012-07-16
- Volume
- 134
- Issue
- 29
- Pages
- 12308-12318
- ISSN
- 0002-7863 (ISSN-L)
- 1520-5126
- OpenAlex
- W2013264850
- Cited by
- 308
- References
- 57
- FWCI
- 7.20
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.